Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASCO 2021 | COVID-19: the growth of telemedicine, oral agents and disruptions in clinical trial operations

Jan Bewersdorf • 24 May 2021

ASCO 2021

General Leukemia Decitabine

Jan Philipp Bewersdorf, MD, Yale School of Medicine, New Haven, CT, discusses the positive and negative impacts of COVID-19 on various issues. Firstly, Dr Bewersdorf explains that many of his patients like the introduction of telemedicine whereby routine check-ups can be done remotely. The trend towards oral treatments can be seen with the approval of oral decitabine, which is bioequivalent to parenteral decitabine. Pharmacodynamic and pharmacokinetic studies of Phase I trials were disrupted and had to be reorganized since the main priority was to keep as many patients as possible out of the hospital. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine

Jan Bewersdorf • 10 Dec 2023

Validation of IWG 2023 criteria for response to treatment with HMA in HR-MDS

Jan Bewersdorf • 10 Dec 2023

E7820 in combination with venetoclax in patients with splicing factor mutant myeloid malignancies

Jan Bewersdorf • 10 Dec 2023

Intensive induction chemotherapy vs HMA/Ven in NPM1-mutant AML: a retrospective study

Jan Bewersdorf • 10 Dec 2023

Related Videos

Optimizing haplo-SCT for the treatment of AML

Arnon Nagler • 16 Apr 2024

HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors

Rémy Duléry • 15 Apr 2024

Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD

Mohamad Mohty • 17 Apr 2024

The consequences of regulatory changes on access to devices and reagents needed for graft processing

Christian Chabannon • 16 Apr 2024